Stem Cell Therapeutics Corp. has announced that it has received notification of the issuance of two additional patents. The first entitled "Use of Luteinizing Hormone (LH) and Chorionic Gonadotropin (hCG) for Proliferation of Neural Stem Cells and Neurogenesis" and was granted by the Australian Patent office; Patent number 2005211847.
The second is entitled "Production of Radial Glial Cells" and was issued by the Canadian Intellectual Property Office; Patent number, 2,364,095.
The first patent expands the geographical coverage of SCT's core neurogenesis technology for increasing neural stem cell numbers, or neurogenesis, by using human chorionic gonadotropin (hCG).
The technology can be used either directly by administration of a therapeutic dose of drug or in the laboratory to expand the numbers of cells that would later be transplanted into a patient or an animal to induce regeneration of neural tissue in the setting of neurodegenerative disease. This patent is the basis for SCT's NTx®-265 therapy.
The second patent protects our exclusive use of specific compounds to induce neurogenesis by identifying radial glial cells (RCGs) as a potentially key central cell type within the neurogenesis process. During early growth RCGs function as neural progenitors in the developing central nervous system (CNS).
This discovery and patent anticipates that proper maturation and migration of neuronal precursors will require RCGs to recapitulate development processes normally quiescent in the 'adult' mammalian brain. Importantly, RCGs are expected to be crucial for the regeneration of damaged or diseased central nervous system tissue.
Similar to the first patent, direct administration of drug or expansion of cells for transplantation is protected in all CNS neurodegenerative diseases and more specifically, Alzheimer's disease, Multiple Sclerosis, Huntington's disease Amyotrophic Lateral Sclerosis or Parkinson's disease.
"SCT's investment in, and commitment to these novel regenerative medical therapies continues to yield an ever stronger and broader patent portfolio", said Dr. Allen Davidoff, Chief Scientific Officer of Stem Cell Therapeutics Corp.
"We are pleased with the steady growth of our patent portfolio during the recent past and look forward to issuance of additional patents from our various applications over the near future. SCT's intellectual property portfolio continues to be a key asset for the company and a coveted, industry-leading technology asset in regenerative medicine."